133230-10-1

Basic information

• Product Name: Benzene, 1-(bromomethyl)-2-chloro-4,5-dimethoxy-
• CAS NO: 133230-10-1
• Molecular Formula: C9H10BrClO2
• Molecular Weight: 265.534
• Mol File: 133230-10-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(bromomethyl)-2-chloro-4,5-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(bromomethyl)-2-chloro-4,5-dimethoxy-(133230-10-1)
• EPA Substance Registry System: Benzene, 1-(bromomethyl)-2-chloro-4,5-dimethoxy-(133230-10-1)

Safety Data

• Hazardous Substances Data: 133230-10-1(Hazardous Substances Data)

Upstream product

• 18093-05-5 6-chloroverataldehyde 
• 20624-89-9 (2-chloro-4,5-dimethoxy-phenyl)-methanol 

Downstream Products

• 143371-58-8 [1-[(S)-7-Benzyloxy-1-(2-chloro-4,5-dimethoxy-benzyl)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-meth-(E)-ylidene]-((S)-1-tert-butoxymethyl-2-methyl-propyl)-amine 
• 1356199-48-8 7-[3-(benzylideneamino)methyl-4-(5'-chloro-3',4'-dimethxoybenzyloxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 
• 1356165-44-0 2-[2-(2-chloro-4,5-dimethoxyphenyl)ethyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1356165-11-1 2-[2-(2-chloro-4,5-dimethoxyphenyl)ethyl]-6,7-dimethoxy-3,4-dihydroisoquinolinium trifluoroacetate 
• 1356165-07-5 1-(2-chloro-4,5-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 56982-07-1 C₂₀H₂₂ClNO₄ 
• 133230-11-2 1-(2'-chloro-4',5'-dimethoxybenzyl)-7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 133320-19-1 dibenzopyrrocoline 
• 143371-58-8 [1-[(S)-7-Benzyloxy-1-(2-chloro-4,5-dimethoxy-benzyl)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-meth-(E)-ylidene]-((S)-1-tert-butoxymethyl-2-methyl-propyl)-amine 

Relevant articles and documents

Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: 90: 1 μg/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 μg/mL). Crown Copyright